F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.
|
|
|
1-10 employees
View all F-star Biotechnology Ltd employees
|
|
Biotechnology
|
|
Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT, GB
|
|
Oncology, Biotech, Cancer Research, Immuno-Oncology, Cancer, Cns, Immunology, Bispecific Antibodies, Immmunotherapy, Tetravalent Bispecifics
|
The decision makers in F-star Therapeutics, Inc. are Rosaleen Mcneill, Rosie Almond - Assoc Cipd, Ryan Fiehler, etc. Click to Find F-star Therapeutics, Inc. decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.